ImmuPharma (LON:IMM) Stock Price Down 15.6% – Should You Sell?

ImmuPharma plc (LON:IMM)’s stock price fell 15.6% during trading on Wednesday . The stock traded as low as GBX 4.60 ($0.06) and last traded at GBX 4.98 ($0.06). 68,204,375 shares traded hands during trading, an increase of 164% from the average session volume of 25,820,418 shares. The stock had previously closed at GBX 5.90 ($0.07).

ImmuPharma Trading Down 15.6 %

The firm has a market capitalization of £20.74 million, a price-to-earnings ratio of -498.00 and a beta of 1.53. The business has a 50-day moving average price of GBX 1.92 and a two-hundred day moving average price of GBX 1.78.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.